Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Jatenzo is a prescription oral testosterone replacement medicine containing testosterone undecanoate. It is indicated for adult males with primary or hypogonadotropic hypogonadism associated with deficient or absent endogenous testosterone. Safety and efficacy are not established for age-related hypogonadism or in males younger than 18.
read more about jatenzo ...Testosterone undecanoate is converted to testosterone after absorption. Testosterone and its active metabolite dihydrotestosterone bind androgen receptors and produce the physiologic effects of endogenous androgens, including maintenance of male reproductive tissues and secondary sex characteristics.
Jatenzo is used in adult males with confirmed hypogonadism caused by specified testicular, pituitary, or hypothalamic conditions. Before treatment begins, low morning testosterone concentrations are confirmed on at least two separate days.
The recommended starting dose is 237 mg by mouth twice daily, once in the morning and once in the evening, with food. Serum testosterone is measured six hours after the morning dose after at least seven days of treatment or a dose change. The dose can range from 158 mg twice daily to 396 mg twice daily according to the testosterone concentration.
Jatenzo can increase blood pressure and is not recommended in men with uncontrolled hypertension. Other serious concerns include polycythemia, venous thromboembolism, worsening benign prostatic hyperplasia, potential prostate cancer risk, edema, sleep apnea, reduced sperm production, testosterone abuse, depression, and suicidal ideation. The previous boxed warning for increased blood pressure was removed from U.S. labeling in 2025.
Jatenzo replaces testosterone in adult males with certain medical conditions that cause deficient or absent endogenous testosterone.
The recommended starting dose is 237 mg twice daily with food.
The dose is adjusted using a serum testosterone concentration measured six hours after the morning dose.
No. The U.S. boxed warning for blood pressure increases was removed in 2025, although blood pressure increases remain a warning and precaution.
A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. https://pubmed.ncbi.nlm.nih.gov/32382745/. Date Accessed October 6, 2026.
JATENZO (Testosterone Undecanoate) Prescribing Information. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed7b5d41-7475-4c10-99b9-b62b3434ae60. Date Accessed October 6, 2026.
JATENZO: Challenges in the Development of Oral Testosterone. https://pubmed.ncbi.nlm.nih.gov/34354245/. Date Accessed October 6, 2026.
Testosterone: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a619028.html. Date Accessed October 6, 2026.
Two-Year Analysis of a New Oral Testosterone Undecanoate Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety. https://pubmed.ncbi.nlm.nih.gov/36272969/. Date Accessed October 6, 2026.